A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, the most deadly form of brain tumors.
Pharmacy Times highlighted a presentation from the University of Cincinnati's Shawn Xiong discussing the potential for artificial intelligence and machine learning to bolster pharmaceutical development and research.